We obtained similar anticancer activity with PP2, a common Src inhibitor, regarding cell proliferation, inhibition of AKT and STAT3 pathways, and cell migration when it was treated to U251 glioma cells (Figure 5). This evidence concerns the gene SRC and glioma.